Research Paper Volume 15, Issue 16 pp 8204—8219
PTPRD mutation is a prognostic biomarker for sensitivity to ICIs treatment in advanced non-small cell lung cancer
Figure 1. Summary of genomic landscape and clinical features associated with response or non-response in NSCLC with immunotherapy. (A, B) OncoPrint that has top 20 gene alterations in DCB group and NDB group. (C) TMB level and PFS were higher in DCB group than NDB group. (D) The Kaplan-Meier plot for NSCLC PFS based on TMB. (E) The Kaplan-Meier plot for NSCLC PFS based on PD-L1 expression. (F) The Kaplan-Meier plot for NSCLC PFS based on treatment line. (G) The Kaplan-Meier plot for NSCLC PFS based on smoking status. (H) The Kaplan-Meier plot for NSCLC PFS based on treatment type. (I) The Kaplan-Meier plot for NSCLC OS based on treatment type.